Department of Medical Microbiology and Parasitology, Faculty of Basic Clinical Sciences, Bayero University, Kano, Nigeria; Department of Clinical Laboratory, Institute of Human Virology, Nigeria
Auto-generated profile, based on publicly available information
Ayuba Bulus Dawurung
Department of Medical Microbiology and Parasitology, Faculty of Basic Clinical Sciences, Bayero University, Kano, Nigeria; Department of Clinical Laboratory, Institute of Human Virology, Nigeria
Objective: There is a need for reliable serological assays to determine accurate estimates of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence. Most single target antigen assays have shown some limitations in Africa. To assess the performance of a multi-antigen assay, we evaluated a commercially available SARS-CoV-2 Multi-Antigen IgG assay for human coronavirus disease 2019 (COVID-19) in Nigeria. Methods: Validation of the xMAP SARS-CoV-2 Multi-Antigen IgG assay was carried out using well-characterized SARS-CoV-2 reverse transcription polymerase chain reactive positive (97) and pre-COVID-19 pandemic (86) plasma panels. Cross-reactivity was assessed using pre-COVID-19 pandemic plasma specimens (213) from the 2018 Nigeria HIV/AIDS Indicator and Impact Survey (NAIIS). Results: The overall sensitivity of the xMAP SARS-CoV-2 Multi-Antigen IgG assay was 75.3% [95% CI: 65.8%– 82.8%] and specificity was 99.0% [95% CI: 96.8%– 99.7%]. The sensitivity estimate increased to 83.3% [95% CI: 70.4%– 91.3%] for specimens >14 days post-confirmation of diagnosis. However, using the NAIIS pre-pandemic specimens, the false positivity rate was 1.4% (3/213). Conclusions: Our results showed overall lower sensitivity and a comparable specificity with the manufacturer’s validation. There appears to be less cross-reactivity with NAIIS pre-pandemic COVID-19 specimens using the xMAP SARS-CoV-2 Multi-Antigen IgG assay. In-country SARS-CoV-2 serology assay validation can help guide the best choice of assays in Africa.
1 January 2025 in African Journal of Laboratory Medicine
Background: Serologic assays can monitor population exposure to pathogens and immunity to vaccine-preventable diseases; the multiplex bead assay (MBA) can test for multiple analytes simultaneously. Intervention: Specimens collected during the Nigeria HIV/AIDS Indicator and Impact Survey (NAIIS) were used to estimate the seroprevalence of diseases of public health importance, and specimens collected from special studies were used to estimate the seroprevalence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to improve the surveillance programmes. In 2019, Luminex MAGPIX® instruments were installed at the MBA laboratory in the National Reference Laboratory, Nigeria Centre for Disease Control and Prevention, in Abuja, Nigeria. Dried blood spot specimens from the NAIIS, stored with consent for future testing, were prioritised for testing. Between 2019 and 2022, the National Reference Laboratory MBA laboratory conducted antibody and antigen assays for an estimated 130 000 NAIIS participants, completed two rounds of coronavirus disease 2019 (COVID-19) serosurveys, and validated SARS-CoV-2 serological assays for use in Nigeria. Lessons learnt: The data generated by the MBA laboratory supported funding requests for childhood immunisation and the application of the National Malaria Elimination Programme Global Fund. The MBA results strengthened the National HIV Serial Rapid Testing Algorithm. During the COVID-19 pandemic, the laboratory validated a SARS-CoV-2 MBA, which measured antibodies against three antigens. This multi-target assay was used to complete two additional rounds of the COVID-19 household serosurvey in Nigeria. Recommendations: This strategy of investing in MBA laboratory capacity building could serve as a model for other nations seeking to fortify their public health infrastructure. What this study adds: Nigeria’s integrated disease surveillance capability was boosted through MBA technology.
14 October 2025 in International Journal of Medical and Health Research
In this study, 324 pregnant women who visited prenatal clinics in Plateau State, Nigeria, had their knowledge, perception, attitude, and preventive actions regarding Zika virus (ZIKV) infection evaluated. Between July 2022 and January 2023, we collected data using a structured questionnaire and a cross-sectional descriptive design. Descriptive statistics and the Chi-square test were used to analyze the data; P<0.05 was considered statistically significant. The results showed that 90.1% of participants lacked knowledge about ZIKV, indicating a significant knowledge gap. The Northern district had the lowest level of knowledge, with an overall knowledge rate of 84.6%, and a statistically significant difference between senatorial districts (P=0.001). Inadequate perception was also reported by 82.4% of respondents; however, district-specific differences were not statistically significant (P=0.064). Most participants held negative opinions about ZIKV (54.6%), with significant differences observed between districts (P=0.001). One particularly concerning finding was that 53.4% of women would not promote condom use or abstinence with a partner who visited an affected area, and 91.0% of women disagreed with delaying conception due to ZIKV concerns. Despite these disparities, a more positive trend in preventive practices was observed; 39.5% of women demonstrated good preventive behaviors, with notable variation among districts (P=0.001). The study’s findings reveal that pregnant women in the area have significant gaps in their understanding, attitudes, and perceptions about ZIKV. These results underscore the urgent need for targeted public health initiatives to increase awareness and protect maternal and fetal health, especially concerning less-known transmission routes and personal protective measures.